Centrum Onkologii Ziemi Lubelskiej Im. Sw. Jana Z Dukli — Clinical Trial Site

68 Registered trials

25 Currently recruiting

Organisation

Centrum Onkologii Ziemi Lubelskiej Im. Sw. Jana Z Dukli

Location

Lublin, Poland

Identifier

ORG-100032537

Address

Ul. Dra Kazimierza Jaczewskiego 7, 20-090, Poland

Departments

-
#048007: I Oddział Onkologii Klinicznej z Chemioterapią Dzienną
161601: Oddział Hematologii i Transplantacji Szpiku
48004: Oddzial Onkologii Klinicznej
5703: I Oddzial Onkologii Klinicznej z Chemioterapią Dzienną
5707: I Oddzial Ginekologii Onkologicznej z Pododdzialem Brachyterapii
Centrum Onkologii Ziemi Lubelskiej im. sw. Jana z Dukli
Hematology
I Chemotherapy Day Unit
I Oddzial Onkologii Klinicznej z Chemioterapia Dzienna
I Oddział Ginekologii Onkologicznej z Pododdziałem Brachyterapii
I Oddział Ginekologii Onkologicznej
I Oddział Ginekologii Onkologicznej z Pododdziałem Brachyterapii
I Oddział Onkologii Klinicznej
I Oddział Onkologii Klinicznej z Chemioterapią Dzienną
I Oddził Onkologii Klinicznej z Chemioterapia Dzienna
II Oddzial Onkologii i Immunologii Klinicznej z Chemioterapia Dzienna
N/A
NA
Oddz. Hematologii i Transplantacji Szpiku z Bankiem Tkanek i Komórek,Pracownią Cytometrii Przepływ.
Oddzia Hematologiczny
Oddzial Hematolog¡i i Transplantacji Szpiku
Oddzial Hematologii i Transplantacji Szpiku
Oddzial Hematologii i Transplantacji Szpiku z Bankiem Tkanek i Komorek
Oddzial Hematologii i Trnsplantacji Szpiku
Oddzial Immunologii Klinicznej i Poradnia Immunologii
Oddzial Onkologii Klinicznej
Oddzial Onkologii Klinicznej z Pododdzialem Chemioterapii Dziennej
Oddział Hematologiczny
Oddział Hematologii i Transplantacji Szpiku
Oddział Hematologii i Transplantacji Szpiku
Oddział Hematologii i Transplantacji Szpiku z Bankiem Tkanek i Komórek
Oddział Hematologii i Transplantacji Szpiku z Bankiem Tkanek i Komórek oraz Pracownią Cytometrii
Oddział Hematologii i Transplantacjii Szpiku
Oddział Onkologii Klinicznej
Oddział Onkologii Klinicznej z Chemioterapią Dzienną
Oncology
Urology Clinic
Zakład Radioterapii

Clinical trials at this site (68)

Search interface

Study to assess the efficacy and safety of Rina-S plus standard of care compared to standard of care for maintenance treatment of participan… Pending

2025-522167-15-00 Ovarian Cancer Platinum-Sensitive Ovarian Cancer (PSOC) 5
A trial to learn how well AZD0120 works and how safe it is in people with relapsed or refractory multiple myeloma. Pending

2025-523285-25-00 Relapsed or Refractory Multiple Myeloma 5
A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma Pending

2025-523815-12-00 Relapsed or Refractory Multiple Myeloma 5
Efficacy and Tolerability of N-AVD compared to BrECADD in patients with advanced Hodgkin Lymphoma (N-BRAVE) Pending

2026-525263-41-00 Hodgkin lymphoma 5
A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab. Recruiting

2025-521639-34-00 • Non-small cell lung cancer (Stage III, unresectable) 3 2026-04-20
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator’s Choice in Participants With Endometrial Cancer ( R… Recruiting

2024-519818-31-01 Endometrial Cancer Advanced, Recurrent, Metastatic, or 5 2026-04-10
Phase 3 Study of Revumenib in Combination with Intensive Chemotherapy in Newly Diagnosed NPM1-mutated AML Recruiting

2025-522279-27-00 Newly Diagnosed AML with an NPM1 mutation 5 2026-04-02
ROSETTA Breast-01: The effects and safety of pumitamig in patients with triple-negative breast cancer Recruiting

2025-521884-12-00 First line triple-negative breast cancer (TNBC) 5 2026-03-19
Study to investigate lifileucel regimen plus pembrolizumab compared with pembrolizumab alone in participants with untreated, advanced melano… Recruiting

2022-503140-41-00 Melanoma 5 2025-12-19
A Phase 3 Single-arm Study of UGN-104 for the Treatment of LG-UTUC Recruiting

2024-519343-15-00 Low-grade Upper Tract Urothelial Cancer 5 2025-10-08
Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast C… Recruiting

2024-515445-42-00 Node-positive, Estrogen Receptor-positive, HER2-negativ 5 2025-03-24
Study BT8009-230 in Subjects with Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) Recruiting

2023-504231-41-01 Locally advanced or metastatic urothelial cancer 4 2024-10-02
A research study to evaluate the safety and effectiveness of Zilovertamab Vedotin with or without Nemtabrutinib in adults with B-cell Malign… Recruiting

2022-501374-19-00 Aggressive and Indolent B-cell Malignancies (mantle cel 4 2022-09-16
An unblinded, multi-center study evaluating long-term treatment with Zanubrutinib (BGB-3111) regimens in patients with blood cancer in the l… Recruiting

2024-511267-28-00 B-cell malignancies 5 2021-02-17
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib plus Ribociclib plus Fulvestrant Versus Placebo plus Ribociclib plus Fulve… Recruiting

2025-523013-28-00 Endocrine-Resistant Hormone-Receptor-Positive, HER2-Neg 4 2026-04-07
Phase III Study of Rilvegostomig in Combination withBevacizumab with or without Tremelimumab as First-lineTreatment of Hepatocellular Carcin… Recruiting

2024-518210-81-00 Advanced Hepatocellular Carcinoma 5 2026-03-18
A trial to learn how safe AZD0486 is and how well it works in older or physically weak adults with large B-cell lymphoma when given after R-… Recruiting

2025-522029-37-00 Large B-cell Lymphoma 5 2026-02-27
A Study of Amivantamab in Addition to Standard of Care Agents Compared with Standard of Care in Participants With Recurrent/Metastatic Head … Recruiting

2025-521917-24-00 Treatment-Naïve Recurrent/Metastatic Head and Neck Squa 5 2026-01-21
A Study to compare RLY-2608 + Fulvestrant with Capivasertib + Fulvestrant in people with PIK3CA-mutated, hormone-receptor positive, HER2-neg… Recruiting

2025-523083-21-00 PIK3CA-mutant Hormone Receptor Positive, Human Epiderma 5 2025-12-08
A Study to Assess safety and Effectiveness of the Inavolisib Plus a CDK4/6 Inhibitor and Letrozole Versus Placebo Plus a CDK4/6 Inhibitor an… Recruiting

2024-516162-11-00 Endocrine-Sensitive phosphatidylinositol 3-kinase (PIK3 5 2025-07-14
A Phase 3 Study of a GPRC5D-directed CAR T Cell Therapy in Participants with Relapsed or Refractory Multiple Myeloma and Exposed to Lenalido… Recruiting

2024-515279-37-00 Relapsed or Refractory and Lenalidomide exposed Multipl 5 2025-04-17
A trial to learn how well saruparib with camizestrant works and how safe it is in adults with advanced breast cancer that is hormone recepto… Recruiting

2023-504180-16-00 Advanced Breast Cancer 5 2025-04-07
Multi-cohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia TAILOR Recruiting

2023-504044-34-00 Untreated Chronic Lymphocytic Leukemia 4 2024-04-17
Iberdomide Manteinance Versus Lenalidomide Manteinance Therapy Following Autologous Stem Cell Transplant in Participants with NDMM Recruiting

2022-501515-14-00 Newly Diagnosed Multiple Myeloma (NDMM) 5 2023-09-29